138 related articles for article (PubMed ID: 10407985)
61. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
62. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A
AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
[TBL] [Abstract][Full Text] [Related]
63. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.
Rimmer Y; Chester J; Joffe J; Stark D; Shamash J; Powles T; White J; Wason J; Parashar D; Armstrong G; Mazhar D; Williams MV
Br J Cancer; 2011 Sep; 105(6):766-72. PubMed ID: 21847130
[TBL] [Abstract][Full Text] [Related]
64. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
Ardizzoni A; Venturini M; Sertoli MR; Giannessi PG; Brema F; Danova M; Testore F; Mariani GL; Pennucci MC; Queirolo P
Br J Cancer; 1994 Feb; 69(2):385-91. PubMed ID: 8297739
[TBL] [Abstract][Full Text] [Related]
65. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
66. [Prophylactic use of hematopoietic growth factors (G-CSF, GM-CSF) in prevention of chemotherapy-induced myelosuppression in children].
Osińska-Królak M; Kurylak A; Wysocki M; Kurylak D; Kindracka A; Balcar-Boroń A
Wiad Lek; 2003; 56(3-4):152-6. PubMed ID: 12923962
[TBL] [Abstract][Full Text] [Related]
67. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
[TBL] [Abstract][Full Text] [Related]
68. Use of GM-CSF in children after high-dose chemotherapy.
Furman WL; Fairclough D; Cain AM; Arnold BA; Pratt CB; Meyer WH; Crist WM
Med Pediatr Oncol Suppl; 1992; 2():26-30. PubMed ID: 1306884
[TBL] [Abstract][Full Text] [Related]
69. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
70. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
71. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
Katakami N; Hasegawa T; Umeda B; Adachi S; Ishii N; Takada Y; Tsubota N; Nakano K; Tamura R; Nakai H
Nihon Kyobu Shikkan Gakkai Zasshi; 1996 May; 34(5):520-8. PubMed ID: 8753109
[TBL] [Abstract][Full Text] [Related]
72. Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
Schirm S; Engel C; Loibl S; Loeffler M; Scholz M
J Cancer Res Clin Oncol; 2018 Feb; 144(2):343-358. PubMed ID: 29103159
[TBL] [Abstract][Full Text] [Related]
73. Clinical trial of recombinant granulocyte colony-stimulating factor for chemotherapy-induced neutropenia patients with oral cancer.
Iwase M; Yoshiya M; Kakuta S; Nagumo M
J Oral Maxillofac Surg; 1997 Aug; 55(8):836-40; discussion 841. PubMed ID: 9251612
[TBL] [Abstract][Full Text] [Related]
74. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
75. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Bajorin DF; Nichols CR; Schmoll HJ; Kantoff PW; Bokemeyer C; Demetri GD; Einhorn LH; Bosl GJ
J Clin Oncol; 1995 Jan; 13(1):79-86. PubMed ID: 7799046
[TBL] [Abstract][Full Text] [Related]
76. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
77. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
[TBL] [Abstract][Full Text] [Related]
78. Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor.
Gurney H; Anderson H; Radford J; Potter MR; Swindell R; Steward W; Kamthan A; Chang J; Weiner J; Thatcher N
Eur J Cancer; 1992; 28(1):105-12. PubMed ID: 1314626
[TBL] [Abstract][Full Text] [Related]
79. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.
Wexler LH; Weaver-McClure L; Steinberg SM; Jacobson J; Jarosinski P; Avila N; Pizzo PA; Horowitz ME
J Clin Oncol; 1996 Mar; 14(3):901-10. PubMed ID: 8622038
[TBL] [Abstract][Full Text] [Related]
80. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]